Beckman Must Boost Lab Device Quality Practices: FDA

Law360, New York (August 23, 2011, 3:18 PM EDT) -- The U.S. Food and Drug Administration has accused lab equipment maker Beckman Coulter Genomics Inc. of inadequate design validation and corrective and preventive action violations based on an investigation at the company's Brea, Calif., facility, according to a warning letter released Tuesday.

The FDA's Aug. 9 warning letter to the company, which was recently acquired by Danaher Corp., concerns Beckman Coulter's diagnostic chemistry analyzers, reagents, calibrators and controls.

A federal inspection of the facility between March and May revealed that, in some cases, methods, facilities or...
To view the full article, register now.